Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04857034 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

A Phase 2 study of Lupus Erythematosus, Discoid and Lupus Erythematosus, Subacute Cutaneous, sponsored by Bristol-Myers Squibb.

Active
Registry status
Phase 2
Development phase
74
Enrollment target
20
Study locations

NCT04857034 is a Phase 2 study of Lupus Erythematosus, Discoid and Lupus Erythematosus, Subacute Cutaneous that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 74 participants, above the 51-participant average among 3 other Lupus Erythematosus, Discoid trials with a reported enrollment target (45% higher). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04857034, a Phase 2 study of Lupus Erythematosus, Discoid and Lupus Erythematosus, Subacute Cutaneous, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
74 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess the safety, efficacy, and tolerability of deucravacitinib (BMS-986165) compared with placebo in participants with active discoid and/or subacute cutaneous lupus erythematosus (DLE/SCLE). This study will also assess if deucravacitinib is biologically active and potentially effective in the treatment of participants with moderate to severe DLE/SCLE with or without systemic lupus erythematosus (SLE) that is not well controlled with standard of care therapy.

Conditions Studied

Lupus Erythematosus, Discoid Lupus Erythematosus, Subacute Cutaneous

Interventions

  • DRUG Placebo
  • DRUG Deucravacitinib

Study Locations (20)

Victoria

  • Local Institution - 0002 - Camberwell
  • Local Institution - 0007 - Clayton
  • Local Institution - 0078 - Melbourne

California

  • Local Institution - 0076 - Irvine
  • Local Institution - 0046 - Los Angeles

New South Wales

  • Local Institution - 0003 - Botany
  • Local Institution - 0001 - Kogarah

Arizona

  • Local Institution - 0077 - Scottsdale

Connecticut

  • Local Institution - 0073 - Farmington

Florida

  • Local Institution - 0082 - Orlando

Michigan

  • Local Institution - 0060 - Ann Arbor

Missouri

  • Local Institution - 0059 - St Louis

Trial Details

FieldValue
Enrollment Target 74 participants
Start Date 2021-07-12
Est. Completion 2028-02-28
Phase Phase 2

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04857034

The ClinicalTrials.gov registry entry for NCT04857034 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 51-participant average among 3 other Lupus Erythematosus, Discoid trials with a reported enrollment target (45% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Lupus Erythematosus, Discoid appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04857034 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Victoria, California, New South Wales.

Frequently Asked Questions

What is clinical trial NCT04857034 about?

NCT04857034 is a clinical study titled "A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)". The purpose of this study is to assess the safety, efficacy, and tolerability of deucravacitinib (BMS-986165) compared with placebo in participants with active discoid and/or subacute cutaneous lupus erythematosus (DLE/SCLE). This study will also assess if deucravacitinib is biologically active and ...

What is the current status of trial NCT04857034?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2021-07-12. Estimated completion is 2028-02-28.

What conditions does trial NCT04857034 study?

This clinical trial studies the following conditions: Lupus Erythematosus, Discoid, Lupus Erythematosus, Subacute Cutaneous.

What interventions are being tested in trial NCT04857034?

The interventions under investigation include: Placebo (DRUG), Deucravacitinib (DRUG).

Who is sponsoring clinical trial NCT04857034?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04857034 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Florida, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lupus Erythematosus, Discoid

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lupus Erythematosus, Discoid

All registered trials for this condition

Lupus Erythematosus, Subacute Cutaneous

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.